What risks do public health agencies face if the public, media, and/or political leaders feel that information about potential treatment options is being withheld? (pg. 10)

What kinds of outreach could public health agencies perform in advance of a crisis to mitigate any perceived lack of transparency? If such a perception emerges in the crisis, then how might it be defused? (pg. 10)

How might federal health authorities avoid people possibly seeing an expedited SPARS vaccine development and testing process as somehow “rushed” and inherently flawed, even though that process still meets the same safety and efficacy standards as any other vaccine? (pg. 13)

What are the potential consequences of health officials over- reassuring the public about the potential risks of a novel SPARS vaccine when long-term effects are not yet known? (pg. 13)

What MCM (Medical Countermeasure) communication challenges and opportunities are likely to emerge among up-and-coming youth audiences who are avid consumers of interactive and visual forms of information? (pg. 22)

Given the ability of powerful, popular figures to reinforce or to undermine public health messages, what steps might health authorities—at either national or local levels—take to reverse the negative effects...? (pg. 28)

Why is active monitoring of the “information sea” in which the public is swimming critical to the efforts of authorities to create conditions and provide information that support recommended public health behaviors? (pg. 39)

How might a strong social media presence allow the federal government—and public health officials more broadly—to anticipate potential communication issues (eg, privacy concerns over using EHR (Electronic Health Records) data to direct vaccination efforts) before they become full-fledged crises? (pg. 39)

What kinds of pre-crisis partnerships and alliances with intermediary groups and/or opinion leaders might have helped to reduce the likelihood and mitigate the impact of anti-Corovax sentiments among specific minority groups? (pg. 48)

Why were partnerships between the federal government and the information technology industry, including a number of social media companies, so vital to increasing overall uptake of the Corovax vaccine? (pg. 58)

What communication strategies might be effective at overcoming the “echo-chamber” effect over the course of the SPARS outbreak? What pre-crisis measures, if any, might have been useful to dampen the “echo-chamber” effect? (pg. 58)

Despite the uncertain science about the link between Coravax and the reported neurological symptoms, why should health officials still communicate with compassion and genuine sympathy toward those in the vaccinated population who experience medical issues subsequent to being vaccinated? (pg. 62)

Given the uncertain long-term safety profile of the Corovax vaccine, why are both science and sympathy necessary when communicating about a possible correlation between vaccination and adverse events? (pg. 65)

What benefits might arise if health authorities publicly share what they have learned from MCM use during the health emergency (including response missteps and successes) and communicate how government agencies plan to evolve on the basis of that information? (pg. 66)